News

Targeted Oncology

Ligufalimab Earns FDA Orphan Drug Designation in AML

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
EconoTimes

Akeso Secures U.S. Orphan Drug Status for Cancer Therapy Ligufalimab

Chinese biotech company Akeso Inc. (HK:9926) announced that its experimental cancer drug ligufalimab (AK117) has received ...
CURE

FDA Grants Orphan Drug Designation to BA-101 in Glioblastoma

The FDA has granted orphan drug designation to the investigational therapy BA-101 for the treatment of patients with ...

NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults

NeuroNOS, a biopharmaceutical company focused on developing treatments for neurological disorders and neuro-oncology, and a subsidiary of Beyond Air (NASDAQ: XAIR), today announced that the U.S. Food ...
Targeted Oncology

FDA Grants Orphan Drug Designation to Novel Glioblastoma Therapy

FDA grants orphan drug designation to BA-101, a promising treatment for glioblastoma, aiming to improve outcomes in this ...
Cure Today

FDA Grants Orphan Status to Liquid Glioma Treatment SH-110

SH-110, a liquid medication for glioma, received FDA orphan drug designation, improving treatment options for patients with swallowing difficulties. Orphan drug status offers incentives such as tax ...
Hosted on MSN

Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...